Why Repligen Corporation’s (RGEN) Stock Is Up 13.09%
As of Tuesday, July 28, Repligen Corporation’s RGEN share price has surged by 13.09%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
What You Need to Know About Repligen Corporation's Q3 Earnings
Repligen Corporation's fiscal Q3 earnings report was released on Tuesday, July 28. Let's dive in to see if (RGEN) missed or beat analyst's expectations.Michael Rose
Why Repligen Corporation’s (RGEN) Stock Is Up 15.89%
As of Tuesday, July 28, Repligen Corporation’s RGEN share price has surged by 15.89%, which has investors questioning if this is right time to sell.Omar Beirat
Is Repligen Corporation (RGEN) Overvalued?
We dive into why Repligen Corporation (RGEN) could be considered overvalued on 2026-07-24, based on AAII’s Value Score and Grade.Michael Rose
Why Repligen Corporation’s (RGEN) Stock Is Down 8.42%
As of Tuesday, July 21, Repligen Corporation’s RGEN share price has dipped by 8.42%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | RGEN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $7,958.0 | $1,790.4 | 74% |
|
| Shares Out (Mil) | 56.6 | 94.8 | 51% |
|
| Institutional Ownership | 99.6% | 90.0% | 91% |
|
| Float (Mil) | 53.4 | 69.9 | 49% |
|
| Beta | 1.06 | 1.20 | 63% |
|
| Avg Daily Volume (000s) | 1,727 | 814 | 79% |
|
| Price Change (52-week) |
14.8% | 80.2% | 57% |
|
| Growth | RGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 15.0% | 7.8% | 73% |
|
| Net Income (5yr) | (4.0%) | (13.7%) | 35% |
|
| EPS (5yr) | (5.0%) | 0.7% | 25 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (24.5%) | (15.0%) | 26% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 17 | 19 | 20 | |
| Current EPS | $0.463 | $2.065 | $2.638 | |
| Month Ago EPS | $0.473 | $2.002 | $2.548 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.517 | $1.968 | $2.517 | |
| Year/Year Chg | 420.2% | 140.1% | 297.7% | |
| Financials | RGEN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $785 | $785 | 47% |
|
| Net Income (TTM) (Mil) | $42 | ($14) | 54% |
|
| EPS (TTM) | $0.737 | ($0.200) | 57% |
|
| Operating Cash Flow (TTM) (Mil) | $135 | $53 | 55% |
|
| Net Cash Flow (TTM) (Mil) | ($100) | ($4) | 14% |
|
| Long-Term Debt (Q1) (Mil) | $672 | $270 | 62% |
|
| Enterprise Value (Q1) (Mil) | $7,985 | $2,444 | 70% |
|
| Valuation | RGEN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.77 | 2.92 | 71% |
|
| P/E | 193.2 | 43.7 | 97% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.3 | na |
|
| Ratios | RGEN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 53.8% | 47.6% | 66% |
|
| Net Margin | 5.3% | (2.9%) | 49% |
|
| ROA | 1.4% | (2.8%) | 51% |
|
| ROE | 2.0% | (4.5%) | 38% |
|
| Liabilities to Assets | 28.4% | 43.0% | 20% |
|
| F-Score | 8 | 5 | 94% |
|
Repligen Corporation did not pass any screens on 7/31/2026.
